Summary of XOMA Corporation FY Conference Call Company Overview - **Company Name**: XOMA Corporation (NasdaqGM:XOMA) - **Enterprise Value**: Approximately $550 million - **Market Capitalization**: Around $450 million - **Cash on Balance Sheet**: About $80 million - **Outstanding Loan**: One loan with Blue Owl for VABYSMO - **Preferred Shares**: Approximately $65 million - **Phase III Assets**: Highest number of Phase III assets in development, totaling about 15 [12][14] Core Strengths and Challenges - **Strengths**: - Largest portfolio of any royalty company with over 120 assets - Profitable products across the portfolio, unlike many biotech companies that are not profitable at launch [12][13] - Unique investment strategy covering the entire drug development spectrum from preclinical to commercial assets [13] - **Challenges**: - Operating with a limited capital situation compared to competitors [21] - Need to manage binary risks associated with biotech investments [14] Portfolio Development Strategy - **Portfolio Building**: - Transitioned from 1 commercial asset to 7 since 2023, focusing on a balanced approach between late-stage and early-stage assets [15] - Emphasis on acquiring undervalued assets in overlooked therapeutic areas [15][16] - **Wind Down Transactions**: - Engaged in transactions where companies pay XOMA cash to acquire assets, generating approximately $12 million in net capital last year [19] - Accumulated about $500 million in tax deductions through these transactions, shielding future profits from federal taxes [20][22] Upcoming Milestones and Catalysts - **Phase III Programs**: - 15 Phase III programs expected to read out over the next 24-30 months, with significant news flow anticipated [29] - Recent Phase III results for Rezolute and Gossamer were unfavorable, but confidence remains in upcoming trials [30][31] - **Regulatory Decisions**: - Anticipated regulatory decisions for MIPLYFFA and Ojenda, with positive developments for ONIVYDE expected to enhance royalty growth [44][46] Market Potential and Product Insights - **Rezolute**: - Market size for tumor hyperinsulinism expected to be significantly larger than congenital hyperinsulinism, with potential revenues exceeding $500 million [50][59] - **MIPLYFFA Launch**: - Exceeded expectations due to rapid patient identification and weight-based dosing advantages [66][70] - **Ovaprene**: - Positioned in the growing non-hormonal market, with expectations for significant market potential as it approaches Phase III trials [78][80] Financial Strategy and Capital Allocation - **Capital Allocation**: - Focus on accumulating assets without significant cash outlays while buying back stock to enhance future returns [88][89] - Interest in acquiring larger biotech companies to access undervalued royalties [91] - **Profitability Outlook**: - Projected profitability by 2027 driven by royalties from MIPLYFFA and Ojenda, alongside VABYSMO [86][87] Conclusion - XOMA Corporation is strategically positioned with a robust portfolio and a focus on risk management and capital efficiency. The company aims to leverage its unique asset base and upcoming milestones to drive shareholder value and achieve profitability in the coming years.

Summary of Day One Biopharmaceuticals FY Conference Call Company Overview - **Company**: Day One Biopharmaceuticals (NasdaqGS:DAWN) - **Industry**: Biopharmaceuticals, focusing on treatments for pediatric patients with life-threatening diseases Key Points and Arguments Product Development and Pipeline - **Ojenda**: Over 1,000 children treated; positioned to become the standard of care for relapsed or refractory pediatric lobar glioma (PLGG) [3][4] - **Firefly-2 Trial**: Enrollment completion anticipated in the first half of 2026, aiming to expand Ojenda's use into frontline PLGG [3][19] - **Acquisition of Mersana**: Completed in Q4 2025, adding the Emmy Lee program to the portfolio, which is expected to contribute significantly to revenue [4][20] - **Day 301 Program**: Early clinical results are promising, with potential applications in multiple adult and pediatric indications [6][23] Financial Performance - **Cash Position**: Ended 2025 with over $440 million in cash and no debt, allowing for continued investment in high-potential programs [5] - **Revenue Growth**: - Q4 2025 net product revenue reached $52.8 million, a 37% increase from Q3 [12] - Full-year 2025 net product revenues totaled $155.4 million, up 172% year-over-year [12] - Guidance for 2026 net product revenue for Ojenda is projected at $225-$250 million [16] Market Dynamics - **Patient Population**: Approximately 1,100 treatment-eligible relapsed refractory PLGG patients annually [17] - **Market Expansion**: Anticipated EME approval in 2026 for global expansion, led by partner Ipsen [17] - **Physician Adoption**: Increasing confidence in multi-year treatments, contributing to growth in patient persistence and treatment duration [17][31] Clinical Data and Efficacy - **Ojenda's Efficacy**: - 19.4 months duration of response and 42.6 months median time to next treatment observed [10] - 75% of patients who took a drug holiday after 24 months remained treatment-free for 12 months [11] - **Emmy Lee Program**: Early evidence of monotherapy efficacy in adenoid cystic carcinoma (ACC), with a potential market opportunity of $300 million [20][21] Strategic Focus - **Dual Growth Model**: Combination of durable revenue from Ojenda and clinical catalysts from new programs like Emmy Lee and Day 301 [24] - **Commitment to Patients**: Focus on developing new medicines that significantly improve patient outcomes [24] Additional Important Content - **Payer Dynamics**: High reimbursement rates (over 90%) and favorable gross-to-net dynamics due to a significant percentage of Medicaid patients [37] - **Physician Education**: Increased efforts in educating physicians and caregivers to improve treatment management and patient outcomes [33][34] - **Future Updates**: Anticipated updates on Emmy Lee and Day 301 programs in mid to late 2026, with a focus on safety and efficacy data [43][44]